Table 3. The difference between the end of run-in period and treatment after 12 weeks .
| Characteristics | Rosuvastatin 10 mg (Group A) (N = 62) | SFC Fenofibrate 80 mg + Rosuvastatin 5 mg (Group B) (N = 50) | p value |
| Waist circumference, cm | -0.49 (5.36) | 0.95 (5.02) | 0.27 |
| Cholesterol, mg/dl | |||
| Total | -7.53 (27.96) (-4.53%) | -0.06 (25.61) (-0.72%) | 0.26 |
| High-density lipoprotein | +2.50 (4.27) (+2.03%) | +0.17 (12.70) (+0.75%) | 0.31 |
| Low-density lipoprotein | -2.17 (23.17) (-9.45%) | +8.26 (21.67) (+7.56%) | 0.07 |
| Non high-density lipoprotein | -7.39 (26.58) (-6.62%) | -0.68 (24.49) (-1.19%) | 0.28 |
| Triglyceride, mg/dl | -36.61 (62.51) (-14.00%) | -44.77 (77.35) (-23.17%) | 0.64 |
| BUN, mg/dl | -0.35 (4.03) | -1.10 (3.55) | 0.84 |
| Creatinine, mg/dl | +0.01 (0.10) | +0.14 (0.28) | 0.07 |
| eGFR, ml/min/m2 | +2.43 (5.02) | -3.76 (8.08) | 0.54 |
| Fasting plasma glucose, mg/dl | -1.44 (10.39) | -0.39 (25.13) | 0.87 |
| HbA1c, % | -0.23 (0.51) | 2.52 (1.55) | 0.36 |
| Liver enzyme, IU/L | |||
| AST | +0.58 (11.62) | +1.28 (22.07) | 0.89 |
| ALT | +2.04 (23.09) | -1.66 (25.89) | 0.58 |
| Creatinine phosphokinase, IU/L | -5.35 (38.89) | -12.67 (48.91) | 0.58 |
| Uric acid, mg/dl | -0.38 (3.20) | -0.23 (0.55) | 0.92 |
Value are presented as mean (SD) (% change) unless stated otherwise.
ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; eGFR, estimated glomerular filtration rate.